In a small clinical trial, the drug Dostarlimab, when given for six months, resulted in the elimination of tumors in all 18 patients. The outcomes were miraculous, and they occurred for the "first time in cancer treatment history."

Dostarlimab, according to experts, acts as a substitute antibody in the human body, rendering cancer undetectable by physical examination, endoscopy, positron emission tomography or PET scans, or MRI scans, demonstrating Dostarlimab′s could act as a ′potential′ cure for one of the most deadly common cancers. Surprisingly, no bowel, urinary, or even sexual dysfunction was observed among the 18 patients who participated in the studies, despite the fact that bowel, urinary, and even sexual dysfunction had previously been recorded in individuals who had had chemotherapy, radiation, or invasive surgery.

Experts stated that the research was impressive because none of the participants experienced serious side effects from the medication trial. According to experts, the patients received Dostarlimab every three weeks for six months during the trial, and no other organs were affected. Also during the follow-up period, no progression or recurrence had been documented. Cancer researchers stated that the treatment seemed to be highly beneficial, but a larger-scale trial is required. (ETHealthWorld, June 08, 2022)